Edifice Health seeks to reinvent immune health and improve healthspan with $12m investment led by Leaps by Bayer.
Stanford spin-out Edifice Health, a Silicon Valley emerging company in immunological health and personalised nutrition has announced a $12 million investment to reinvent immune health, improve healthspan, and change the course of aging.
Longevity.Technology: With funding led by Leaps by Bayer, Edifice aims to harness previously unattainable insights into the root causes of chronic diseases of aging through its highly-differentiated approach. It plans to deliver highly-personalised interventions to improve inflammatory and immune health, and to extend healthspan. Paladin Capital Group, Vertical Venture Partners, Ahren Innovation Capital, Ataraxia Capital Partners, Shanda Grab Ventures, Alafi Capital and Taisho Pharmaceutical also participated in the round. Seed stage investors include Human Longevity and Performance Impact Venture Fund, Longevity Incubator Fund, Summer Venture Capital, Carlyle Global Advisors, M4 Capital GmbH, and Better Food Ventures.
Globally, about 71% of annual deaths are attributable to non-communicable diseases of aging, which include cancer, cardiovascular diseases, Type II diabetes, neurodegenerative disorders and depression. According to the US Centers for Disease Control (CDC), 90% of the US’s staggering $3.8 trillion in annual heath care expenditures are attributable to chronic health conditions.
“We are thrilled to be able to invest in this groundbreaking technology… which provides consumers with the first trackable biomarker for systemic chronic inflammation and safe supplements that can reduce inflammation, improve healthspan, and change the course of aging,”
Wolfgang Daum, PhD, Edifice’s Chairman and CEO, and a serial life science entrepreneur, remarked that, to date, the absence of a measurable biomarker to detect the root cause of these non-communicable diseases has been the main barrier to quickly diagnosing, treating and even preventing them, adversely impacting the healthspans of afflicted people. His company, Edifice, intends to change that and this investment will support the company in rapidly growing its solid foundation of immunological science and adding additional talent eager to disrupt the industry.
Edifice was born out of the Stanford 1,000 Immunomes’ Project following the 10-year National Institute of Health-funded research in immunological health and aging at Stanford University. The company uses novel proteomic approaches and combines them with proprietary AI and predictive analysis to measure the rate at which an individual’s body ages. Edifice has created a first-ever metric to measure systemic chronic inflammation, which, the Stanford Project research showed to be the root cause – and thus, the predictor – of multiple chronic diseases of aging. Furthermore, the company has identified interventional supplements, which can be highly targeted to an individual’s immunotype to improve inflammatory health and facilitate healthy aging.
“We are thrilled to be able to invest in this groundbreaking technology firmly rooted within our leap #10 to drive transformational digital business models and based on a very credible scientific foundation from Stanford which provides consumers with the first trackable biomarker for systemic chronic inflammation and safe supplements that can reduce inflammation, improve healthspan, and change the course of aging,” said Juergen Eckhardt, Head of Leaps by Bayer.
Edifice will combine its inflammatory health technology with a consumer and market-centric product expected to launch next year. Future interventions to extend health spans would include pharmaceutical applications targeting specific disease states, partnering with various companies to dramatically scale Edifice’s mission of extending healthy aging through food, beverage and nutritional products.
